Literature DB >> 16138102

Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation.

Warren J Leonard1, Rosanne Spolski.   

Abstract

The interleukin-21 (IL-21)-IL-21-receptor system was discovered in 2000. It was immediately of great interest because of the homology of IL-21 to IL-2, IL-4 and IL-15, and of the IL-21-receptor subunit IL-21R to the beta-subunit of the IL-2 receptor, and because the IL-21 receptor also contains the common cytokine-receptor gamma-chain, the protein that is mutated in X-linked severe combined immunodeficiency. As we discuss, IL-21 has pleiotropic actions, from augmenting the proliferation of T cells and driving the differentiation of B cells into memory cells and terminally differentiated plasma cells to augmenting the activity of natural killer cells. Moreover, it has antitumour activity and might have a role in the development of autoimmunity, so these findings have implications for the treatment of cancer and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138102     DOI: 10.1038/nri1688

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  157 in total

Review 1.  A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis.

Authors:  Brian Astry; Erin Harberts; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

Review 2.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

Review 3.  Understanding the development and function of T follicular helper cells.

Authors:  Roza I Nurieva; Yeonseok Chung
Journal:  Cell Mol Immunol       Date:  2010-04-12       Impact factor: 11.530

4.  IL-21 is required for CD4 memory formation in response to viral infection.

Authors:  Yuqing Yuan; Yiping Yang; Xiaopei Huang
Journal:  JCI Insight       Date:  2017-04-06

5.  Interleukin-21 is associated with disease activity in patients with Graves' disease.

Authors:  Jin Zhang; Hua Zeng; Meng Ren; Haiyan Yan; Mingtong Xu; Zhimei Feng; Weiwen Liang; Chuan Yang; Hua Cheng; Helin Ding; Li Yan
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

6.  IL-21 mediates suppressive effects via its induction of IL-10.

Authors:  Rosanne Spolski; Hyoung-Pyo Kim; Wei Zhu; David E Levy; Warren J Leonard
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases.

Authors:  Alexandra Zhernakova; Behrooz Z Alizadeh; Marianna Bevova; Miek A van Leeuwen; Marieke J H Coenen; Barbara Franke; Lude Franke; Marcel D Posthumus; David A van Heel; Gerrit van der Steege; Timothy R D J Radstake; Pilar Barrera; Bart O Roep; Bobby P C Koeleman; Cisca Wijmenga
Journal:  Am J Hum Genet       Date:  2007-10-24       Impact factor: 11.025

8.  IL-21 accelerates xenogeneic graft-versus-host disease correlated with increased B-cell proliferation.

Authors:  Xiaoran Wu; Yi Tan; Qiao Xing; Shengdian Wang
Journal:  Protein Cell       Date:  2013-11-10       Impact factor: 14.870

9.  The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells.

Authors:  Chi-Keung Wan; Jangsuk Oh; Peng Li; Erin E West; Elizabeth A Wong; Allison B Andraski; Rosanne Spolski; Zu-Xi Yu; Jianping He; Brian L Kelsall; Warren J Leonard
Journal:  Immunity       Date:  2013-02-28       Impact factor: 31.745

10.  Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.

Authors:  Aruna Gowda; Asha Ramanunni; Carolyn Cheney; Darlene Rozewski; Wayne Kindsvogel; Amy Lehman; David Jarjoura; Michael Caligiuri; John C Byrd; Natarajan Muthusamy
Journal:  MAbs       Date:  2010-01-08       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.